Literature DB >> 31665830

Identification of CFTR variants in Latino patients with cystic fibrosis from the Dominican Republic and Puerto Rico.

Andrew M Zeiger1, Meghan E McGarry2, Angel C Y Mak1, Vivian Medina3, Sandra Salazar1, Celeste Eng1, Amy K Liu1, Sam S Oh1, Thomas J Nuckton1, Deepti Jain4, Thomas W Blackwell5, Hyun Min Kang5, Goncalo Abecasis5, Leandra Cordero Oñate6, Max A Seibold7, Esteban G Burchard1,8, Jose Rodriguez-Santana3.   

Abstract

BACKGROUND: In cystic fibrosis (CF), the spectrum and frequency of CFTR variants differ by geography and race/ethnicity. CFTR variants in White patients are well-described compared with Latino patients. No studies of CFTR variants have been done in patients with CF in the Dominican Republic or Puerto Rico.
METHODS: CFTR was sequenced in 61 Dominican Republican patients and 21 Puerto Rican patients with CF and greater than ​​​​60 mmol/L sweat chloride. The spectrum of CFTR variants was identified and the proportion of patients with 0, 1, or 2 CFTR variants identified was determined. The functional effects of identified CFTR variants were investigated using clinical annotation databases and computational prediction tools.
RESULTS: Our study found 10% of Dominican patients had two CFTR variants identified compared with 81% of Puerto Rican patients. No CFTR variants were identified in 69% of Dominican patients and 10% of Puerto Rican patients. In Dominican patients, there were 19 identified CFTR variants, accounting for 25 out of 122 disease alleles (20%). In Puerto Rican patients, there were 16 identified CFTR variants, accounting for 36 out of 42 disease alleles (86%) in Puerto Rican patients. Thirty CFTR variants were identified overall. The most frequent variants for Dominican patients were p.Phe508del and p.Ala559Thr and for Puerto Rican patients were p.Phe508del, p.Arg1066Cys, p.Arg334Trp, and p.I507del.
CONCLUSIONS: In this first description of the CFTR variants in patients with CF from the Dominican Republic and Puerto Rico, there was a low detection rate of two CFTR variants after full sequencing with the majority of patients from the Dominican Republic without identified variants.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  CFTR variants; Latino; health disparities; whole genome sequencing

Mesh:

Substances:

Year:  2019        PMID: 31665830      PMCID: PMC7571374          DOI: 10.1002/ppul.24549

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  37 in total

1.  Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population.

Authors:  Glenn E Palomaki; Stacey C FitzSimmons; James E Haddow
Journal:  Genet Med       Date:  2004 Sep-Oct       Impact factor: 8.822

2.  Hispanic Infants with cystic fibrosis show low CFTR mutation detection rates in the Illinois newborn screening program.

Authors:  Kimberly Danieli Watts; Benjamin Layne; Ann Harris; Susanna A McColley
Journal:  J Genet Couns       Date:  2012-02-04       Impact factor: 2.537

3.  Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis.

Authors:  Meghan E McGarry; John M Neuhaus; Dennis W Nielson; Esteban Burchard; Ngoc P Ly
Journal:  Pediatr Pulmonol       Date:  2017-10-30

4.  Classification of CFTR mutation classes.

Authors:  Fernando Augusto Lima Marson; Carmen Sílvia Bertuzzo; José Dirceu Ribeiro
Journal:  Lancet Respir Med       Date:  2016-07-01       Impact factor: 30.700

5.  Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation.

Authors:  Philip M Farrell; Terry B White; Clement L Ren; Sarah E Hempstead; Frank Accurso; Nico Derichs; Michelle Howenstine; Susanna A McColley; Michael Rock; Margaret Rosenfeld; Isabelle Sermet-Gaudelus; Kevin W Southern; Bruce C Marshall; Patrick R Sosnay
Journal:  J Pediatr       Date:  2017-02       Impact factor: 4.406

6.  Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry.

Authors:  M J Alonso; D Heine-Suñer; M Calvo; J Rosell; J Giménez; M D Ramos; J J Telleria; A Palacio; X Estivill; T Casals
Journal:  Ann Hum Genet       Date:  2007-03       Impact factor: 1.670

7.  Cystic-fibrosis-like disease unrelated to the cystic fibrosis transmembrane conductance regulator.

Authors:  F Mekus; M Ballmann; I Bronsveld; T Dörk; J Bijman; B Tümmler; H J Veeze
Journal:  Hum Genet       Date:  1998-05       Impact factor: 4.132

8.  Identification of novel and rare mutations in California Hispanic and African American cystic fibrosis patients.

Authors:  Ozgül M Alper; Lee-Jun C Wong; Suzanne Young; Michelle Pearl; Steve Graham; John Sherwin; Eliezer Nussbaum; Dennis Nielson; Arnold Platzker; Zoe Davies; Allan Lieberthal; Terry Chin; Greg Shay; Karen Hardy; Martin Kharrazi
Journal:  Hum Mutat       Date:  2004-10       Impact factor: 4.878

9.  LUMPY: a probabilistic framework for structural variant discovery.

Authors:  Ryan M Layer; Colby Chiang; Aaron R Quinlan; Ira M Hall
Journal:  Genome Biol       Date:  2014-06-26       Impact factor: 13.583

10.  CADD: predicting the deleteriousness of variants throughout the human genome.

Authors:  Philipp Rentzsch; Daniela Witten; Gregory M Cooper; Jay Shendure; Martin Kircher
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

View more
  3 in total

1.  Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype.

Authors:  Meghan E McGarry; Susanna A McColley
Journal:  Pediatr Pulmonol       Date:  2021-02-01

Review 2.  Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis.

Authors:  Meghan E McGarry; Elizabeth R Gibb; Gabriela R Oates; Michael S Schechter
Journal:  Paediatr Respir Rev       Date:  2021-12-22       Impact factor: 5.526

3.  The QChip1 knowledgebase and microarray for precision medicine in Qatar.

Authors:  Juan L Rodriguez-Flores; Radja Messai-Badji; Amal Robay; Asmaa Althani; Ronald G Crystal; Ramzi Temanni; Najeeb Syed; Monika Markovic; Eiman Al-Khayat; Fatima Qafoud; Zafar Nawaz; Ramin Badii; Yasser Al-Sarraj; Hamdi Mbarek; Wadha Al-Muftah; Muhammad Alvi; Mahboubeh R Rostami; Juan Carlos Martinez Cruzado; Jason G Mezey; Alya Al Shakaki; Joel A Malek; Matthew B Greenblatt; Khalid A Fakhro; Khaled Machaca; Ajayeb Al-Nabet; Nahla Afifi; Andrew Brooks; Said I Ismail
Journal:  NPJ Genom Med       Date:  2022-01-19       Impact factor: 6.083

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.